Journal article
Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.
Abstract
7004
Background: The TAILORx study demonstrated women with an intermediate Oncotype DX score receive the same benefit with endocrine therapy (ET) compared to chemoendocrine therapy (CET). However, early discontinuation of adjuvant ET is problematic among breast cancer survivors, with previous studies suggesting that up to 50% of women do not adhere to the full 5 years of recommended ET treatment. The aim of this study was to …
Authors
Yanez B; Gray RJ; Sparano JA; Carlos R; Sadigh G; Garcia SF; Gareen IF; Whelan TJ; Sledge GW; Cella D
Journal
Journal of Clinical Oncology, Vol. 38, No. 15_suppl, pp. 7004–7004
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2020
DOI
10.1200/jco.2020.38.15_suppl.7004
ISSN
0732-183X